[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1283
1. Bramwell V: When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma. Oncology (Williston Park); 2007 Apr;21(4):511-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma.
  • In patients with adult soft-tissue sarcoma (ASTS), the use and timing of adjuvant chemotherapy or chemoradiotherapy remains controversial.
  • [MeSH-major] Neoadjuvant Therapy. Neoplasm Recurrence, Local. Sarcoma / drug therapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Meta-Analysis as Topic. Randomized Controlled Trials as Topic. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474349.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  •  go-up   go-down


2. Jain A, Sajeevan KV, Babu KG, Lakshmaiah KC: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer; 2009 Oct-Dec;46(4):274-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in adult soft tissue sarcoma.
  • Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms.
  • Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma.
  • We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma.
  • Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoadjuvant Therapy


3. Nunes LF, Fiod NJ, Vasconcelos RA, Meohas W, Rezende JF: [Epithelioid sarcoma: clinical behavior, prognostic factors and survival]. Rev Col Bras Cir; 2010 Aug;37(4):251-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelioid sarcoma: clinical behavior, prognostic factors and survival].
  • [Transliterated title] Sarcoma epitelióide: aspectos clínicos, fatores prognósticos e sobrevida.
  • METHODS: Careful analysis of 25 epithelioid sarcoma cases registered in Instituto Nacional do Cancer between june 1987 and july 2005.
  • CONCLUSION: Epithelioid sarcoma is a rare subset of soft tissue sarcoma with high rate of local recurrence, regional node and distant metastases.
  • Surgical treatment of epithelioid sarcoma consists of early wide local resection to negative microscopic margins.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / mortality. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21085839.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M, Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer; 2008 Mar 15;112(6):1197-205
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review.
  • A systematic review was performed to determine whether first-line dose-intensive chemotherapy supported by growth factor or autologous bone marrow/stem cell transplantation improves response rate, time-to-disease progression, or survival compared with standard-dose chemotherapy in patients with inoperable, locally advanced, or metastatic soft tissue sarcoma.
  • On the basis of the available evidence, high-dose chemotherapy with growth factor or autologous bone marrow/stem cell transplantation should not be used in the routine treatment of patients with inoperable, locally advanced, or metastatic soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Growth Substances / administration & dosage. Sarcoma / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18224666.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances
  • [Number-of-references] 35
  •  go-up   go-down


5. Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C, Gronchi A: Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann Surg Oncol; 2006 Jan;13(1):110-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity.
  • BACKGROUND: We explored the outcome of patients with primary adult soft tissue sarcoma (STS) of the extremities undergoing re-excision after previous unplanned surgery.
  • METHODS: A total of 597 consecutive adult patients with primary extremity STS were treated with conservative surgery at our institution over a 20-year time span.
  • The assessed end points were sarcoma-specific mortality, local recurrence, and distant metastasis.
  • CONCLUSIONS: At a referral center with a liberal policy of re-excisions in adult primary STS of the extremities, the outcome of patients who underwent re-excision was similar to that of patients who had primary resections.
  • [MeSH-major] Neoplasm, Residual / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Extremities. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Regression Analysis. Reoperation. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372156.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Verma S, Younus J, Haynes AE, Stys-Norman D, Blackstein M, Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline. Curr Oncol; 2008 Apr;15(2):80-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline.
  • QUESTIONS: In patients with inoperable locally advanced or metastatic soft tissue sarcoma, does first-line dose-intensive chemotherapy supported by growth factor or autologous bone marrow or stem-cell transplantation improve response rate, time to disease progression, or survival as compared with standard-dose chemotherapy?
  • PERSPECTIVES: Because therapeutic options for adult patients with advanced or metastatic soft tissue sarcoma are scarce and the possibility of cure for these patients is extremely limited, the Sarcoma Disease Site Group (dsg) felt that a review of the available literature on dose-intensive chemotherapy for adult patients with locally advanced or metastatic soft tissue sarcoma and subsequent development of a clinical practice guideline based on the evidence were important.
  • The practice guideline report was reviewed and approved by the Sarcoma dsg, which comprises medical oncologists, radiation oncologists, surgeons, a pathologist, a methodologist, and community representatives.
  • PRACTICE GUIDELINE: Based on the systematic review, consensus, and external review, the Sarcoma dsg makes these recommendations: Dose-intensive chemotherapy with growth factor support is not recommended in the first-line treatment of patients with inoperable locally advanced or metastatic soft tissue sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Feb 15;77(4):675-82 [8616759.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S194-8 [8453697.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1551-8 [9389914.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):871-6 [9789610.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):917-9 [9789617.001]
  • [Cites] Am J Clin Oncol. 1999 Jun;22(3):267-72 [10362334.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2676-84 [10894866.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1498-506 [15042685.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):105-12 [15625365.001]
  • [Cites] Cancer Treat Rep. 1985 May;69(5):499-504 [3924401.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S180-4 [8453694.001]
  • [Cites] Am J Clin Oncol. 1996 Feb;19(1):78-81 [8554042.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1221-7 [9317171.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1438-43 [9552049.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):66-72 [10211090.001]
  • [Cites] Tumori. 1999 Jul-Aug;85(4):229-33 [10587022.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):161-6 [11863099.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2629-36 [7595717.001]
  • [Cites] J Surg Oncol. 1995 Jun;59(2):110-5 [7776651.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1418-26 [9193334.001]
  • (PMID = 18454188.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2365487
  • [Keywords] NOTNLM ; Soft tissue sarcoma / autologous bone marrow or stem-cell transplantation / clinical practice guideline / dose-intensive chemotherapy / growth factor
  •  go-up   go-down


7. Schwarzbach MH, Hormann Y, Hinz U, Bernd L, Willeke F, Mechtersheimer G, Böckler D, Schumacher H, Herfarth C, Büchler MW, Allenberg JR: Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity. J Vasc Surg; 2005 Jul;42(1):88-97
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity.
  • OBJECTIVE: To evaluate limb-salvage surgery with vascular resection for lower extremity soft tissue sarcomas (STS) in adult patients and to classify blood vessel involvement.
  • METHODS: Subjects were consecutive patients (median age, 56 years) who underwent vascular replacement during surgery of STS in the lower limb between January 1988 and December 2003.
  • Blood vessel involvement by STS was classified as follows: type I, artery and vein; type II, artery only; type III, vein only; and type IV, neither artery nor vein (excluded from the analysis).
  • RESULTS: Twenty-one (9.9%) of 213 patients underwent vascular resections for lower limb STS.
  • Besides 17 type I tumors (81.0%), 3 (14.3%) type II and 1 (4.7%) type III STS were diagnosed.
  • CONCLUSIONS: Long-term bypass patency rates, the high percentage of limb salvage, and the oncologic outcome underline the efficacy of en bloc resection of STS involving major vessels in the lower limb.
  • [MeSH-major] Blood Vessel Prosthesis Implantation. Limb Salvage. Sarcoma / surgery. Vascular Neoplasms / surgery

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012457.001).
  • [ISSN] 0741-5214
  • [Journal-full-title] Journal of vascular surgery
  • [ISO-abbreviation] J. Vasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polyethylene Terephthalates; 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


8. Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D: Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer; 2010;10:132
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.
  • However, only a few studies investigated the prognostic impact of expression of OPN in soft tissue sarcomas (STS) yet.
  • METHODS: This study is based on tumor and serum samples from 93 adult STS patients.
  • We investigated OPN protein levels in serum (n = 86) and tumor tissue (n = 80) by ELISA and OPN mRNA levels in tumor tissue (n = 68) by quantitative real-time PCR.
  • RESULTS: No correlation was found between OPN levels in serum and tumor tissue.
  • OPN protein levels in the tumor tissue were associated with higher stage (p = 0.06), higher grade (p = 0.003), subtype (p = 0.07) and an increased rate of relapse (p = 0.02).
  • In addition, using a Cox's proportional hazards regression model, we found that an elevated OPN protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for patients with STS.
  • CONCLUSION: Our data suggest OPN protein in serum as well as in tumor tissue extracts is an important prognostic factor for soft tissue sarcoma patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Osteopontin / metabolism. Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Hypoxia / physiology. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3419-27 [17896150.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7170-4 [17525744.001]
  • [Cites] Cell Mol Biol Lett. 2008;13(1):11-9 [17952379.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):103-18 [18049863.001]
  • [Cites] Curr Med Chem. 2008;15(4):322-38 [18288988.001]
  • [Cites] Head Neck. 2008 Jun;30(6):776-81 [18228527.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Aug;134(8):909-17 [18210151.001]
  • [Cites] Lab Invest. 2008 Dec;88(12):1264-77 [18838962.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6B):4105-10 [19192668.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):118-30 [10825241.001]
  • [Cites] Cancer Lett. 2001 Sep 20;170(2):199-205 [11463499.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):668-74 [11764388.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Curr Mol Med. 2001 Nov;1(5):621-32 [11899236.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):943-5 [11918915.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]
  • [Cites] Virchows Arch. 2002 Oct;441(4):345-9 [12404059.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1098-104 [12631613.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1588-96 [15014008.001]
  • [Cites] Eur J Cancer. 1993;29A(15):2089-93 [8297645.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):453-7 [16091764.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):740-6 [15970685.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8019-27 [16299231.001]
  • [Cites] Cancer Biol Ther. 2005 Dec;4(12):1336-41 [16258259.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2192-202 [16288209.001]
  • [Cites] BMC Cancer. 2006;6:207 [16911785.001]
  • [Cites] BMC Cancer. 2006;6:237 [17022822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7 [17056190.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):81-90 [17150036.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):98-102 [16675104.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Feb;292(2):C919-26 [17005603.001]
  • [Cites] Radiother Oncol. 2007 Jun;83(3):389-97 [17499868.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6361-71 [17452979.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):889-97 [17960616.001]
  • (PMID = 20377868.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2856551
  •  go-up   go-down


9. Abraham JA, Baldini EH, Butrynski JE: Management of adult soft-tissue sarcoma of the extremities and trunk. Expert Rev Anticancer Ther; 2010 Feb;10(2):233-48
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adult soft-tissue sarcoma of the extremities and trunk.
  • Soft-tissue sarcomas are a heterogeneous group of tumors consisting of approximately 100 distinct diagnoses.
  • [MeSH-major] Sarcoma / surgery
  • [MeSH-minor] Adult. Extremities. Humans. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131999.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Lordick F: [Multidisciplinary treatment for adult soft tissue sarcoma]. Chirurg; 2009 Mar;80(3):209-15
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multidisciplinary treatment for adult soft tissue sarcoma].
  • The current standard in local treatment of soft tissue sarcomas has shifted from amputation and similar mutilating resections to more organ- and function-preserving surgery.
  • Progress may occur when the pathogenesis and molecular profile of specific sarcoma subtypes are better understood, allowing more effective new drugs.
  • Presently the most effective measure to improve the prognosis with soft tissue sarcomas is early patient referral to expert centres, where diagnostic workup and therapy decisions are made on a multidisciplinary basis and updated according to the newest guidelines and study results.
  • [MeSH-major] Patient Care Team. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Cooperative Behavior. Disease-Free Survival. Humans. Interdisciplinary Communication. Neoadjuvant Therapy. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156392.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


11. Qiu MZ, Xu F, Wang SS, Luo HY, Wang F, Li FH, Sun XF, Xu GC, Lin TY, Huang HQ, Jiang WQ, Guan ZZ, Xu RH: [Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. Ai Zheng; 2007 Dec;26(12):1344-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
  • BACKGROUND & OBJECTIVE: The response of adult soft tissue sarcoma (STS) to chemotherapy is uncertain.
  • This study was to evaluate the role of chemotherapy in treating adult soft tissue sarcoma.
  • METHODS: Clinical data of 109 adult soft tissue sarcoma patients, treated with chemotherapy at Cancer Center of Sun Yat-sen University from Jan.
  • CONCLUSIONS: MAID and CYVADIC are two effective chemotherapy regimens for adult soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Extremities. Pelvic Neoplasms / drug therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Mesna / therapeutic use. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Palliative Care. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076798.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; CYVADIC protocol; MAID protocol
  •  go-up   go-down


12. Tunn PU, Kettelhack C, Dürr HR: Standardized approach to the treatment of adult soft tissue sarcoma of the extremities. Recent Results Cancer Res; 2009;179:211-28
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardized approach to the treatment of adult soft tissue sarcoma of the extremities.
  • Soft tissue sarcomas are very rare tumors.
  • Furthermore, universally accepted treatment protocols for adult patients are lacking.
  • Several prognostic factors have been identified, including grading, tumor size and development of metastatic disease; however, the relevance of other important aspects in the treatment of patients with soft tissue sarcomas remains unknown or subject to controversy.
  • [MeSH-major] Extremities / pathology. Extremities / surgery. Sarcoma / therapy
  • [MeSH-minor] Adult. Humans

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230542.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 84
  •  go-up   go-down


13. Lubieniecka JM, Nielsen TO: cDNA microarray-based translational research in soft tissue sarcoma. J Surg Oncol; 2005 Dec 15;92(4):267-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] cDNA microarray-based translational research in soft tissue sarcoma.
  • The authors discuss application of cDNA microarray technology in translational research to identify diagnostic markers and therapeutic targets in adult soft tissue sarcoma.
  • Recent results in synovial sarcoma are used to highlight the applicability of this technology for marker and target discovery, as well as the need for preclinical validation of putative therapeutic targets.
  • [MeSH-major] Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Sarcoma / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adult. Gastrointestinal Stromal Tumors / genetics. Humans. Molecular Diagnostic Techniques. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / genetics

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16299802.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Editorial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Badellino F, Toma S: Treatment of soft tissue sarcoma: a European approach. Surg Oncol Clin N Am; 2008 Jul;17(3):649-72, x
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of soft tissue sarcoma: a European approach.
  • This article discusses the treatment of adult soft tissue sarcoma (excluding gastrointestinal stromal tumor), analyzing the principles underlying treatment and the results of surgery, radiotherapy, and chemotherapy.
  • [MeSH-major] Sarcoma / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486888.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 82
  •  go-up   go-down


15. Hartmann JT, Patel S: New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep; 2005 Jul;7(4):300-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New drug developments for patients with metastatic soft tissue sarcoma.
  • However, the number of effective cytotoxic agents for the treatment of patients with metastatic so-called adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Curr Oncol Rep. 2012 Apr;14(2):220 [22371000.001]
  • (PMID = 15946590.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


16. Pink D, Rahm J, Schoeler D, Schoenknecht TM, Reichardt P: Activity of paclitaxel in radiation induced and other secondary angiosarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):10578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10578 Background: Angiosarcomas (AS) represent 1-2% of adult soft tissue sarcomas and can arise anywhere in the body.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Italiano A, Delva F, Brouste V, Terrier P, Trassard M, Michels J, Collin F, Coindre J, Blay J, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database. J Clin Oncol; 2009 May 20;27(15_suppl):10504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database.
  • : 10504 Background: The SMAC meta-analysis failed to demonstrate that adjuvant chemotherapy (AC) significantly improves overall survival (OS) in adult patients with localised resectable soft-tissue sarcoma (STS).
  • We report here the analysis of the impact of AC in the population of STS patients included in the prospective database of the French Sarcoma Group.
  • METHODS: Between 1980 and 1999, 2,029 pts with STS were admitted to one of the 20 tertiary cancer centers of the GSF for the management of a first tumoral event and were included prospectively in a comprehensive database.
  • The commonest pathological subtypes were MFH 22.5%, liposarcoma 18%, leiomyosarcoma 13%, and synovial sarcoma 10%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Dileo P, Bertulli R, Piovesan C, Marrari A, Puma E, Spreafico C, Gronchi A, Olmi P, Gandola L, Casali PG: Long-term results with combined treatment in adult localized extraskeletal Ewing's sarcoma (ES): A retrospective analysis of 51 patients (pts) from a single referral center. J Clin Oncol; 2009 May 20;27(15_suppl):10548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results with combined treatment in adult localized extraskeletal Ewing's sarcoma (ES): A retrospective analysis of 51 patients (pts) from a single referral center.
  • : 10548 Background: After the first description in 1975, only small series of adult extraskeletal ES have been reported.
  • METHODS: We retrospectively reviewed adult pts with extraskeletal, localized ES, undergoing medical therapy between 1988 and 2004, who were included in the dataset of the current Adult Sarcoma Medical Unit at Istituto Nazionale Tumori, Milano, Italy, which serves as a reference center for adult soft tissue sarcoma.
  • CONCLUSIONS: In this series of adult pts with extraskeletal ES, response rate and DFS were comparable to those of ES of bone in conventional series.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963955.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Gronchi A, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L, Casali PG: Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann Surg Oncol; 2007 May;14(5):1583-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure.
  • BACKGROUND: We explored the prognostic meaning of local relapse and surgical margins in adult soft tissue sarcoma of the extremities.
  • METHODS: Out of a series of 1017 patients with extremity soft tissue sarcoma treated over 20 years, we picked a group of 238 patients operated on at our institution for their first local relapse: 88 after their primary operation performed at the same center and 150 elsewhere.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lower Extremity / pathology. Male. Middle Aged. Neoplasm Metastasis / pathology. Prognosis. Survival Rate. Treatment Failure. Upper Extremity / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 May;14(5):1528-9 [17295083.001]
  • (PMID = 17260106.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hartmann JT, Patel S: Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs; 2005;65(2):167-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
  • The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.
  • Small round cell tumours (SRCTs), such as Ewing's sarcoma/primitive neuroectodermal tumour, desmoplastic SRCT and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensive, neoadjuvant protocols regardless of size or overt metastatic disease.
  • Most other high-grade (grading >I), so-called 'adult type', soft tissue sarcomas such as fibrosarcoma, liposarcoma, pleomorphic and synovial sarcomas are treated with an anthracycline-based regimen with or without ifosfamide as front-line therapy.
  • In relapsed 'adult type' soft tissue sarcomas, trofosfamide, gemcitabine and trabectedin (ecteinascidin 743) appear to be drugs associated with some activity and an acceptable toxicity profile.
  • A high activity has been reported for the taxanes, in particular for paclitaxel, in vascular sarcomas located in the scalp or face and in Kaposi's sarcoma.
  • It is interesting to note that the different drugs have particular effects in distinct subtypes of soft tissue sarcoma; however, it should be taken into account that the number of patients included in the phase II trials is limited.
  • Targeted therapy inhibiting vascular endothelial growth factor receptor, epidermal growth factor receptor, RAF kinase, c-KIT or platelet-derived growth factor receptors will continue to be tested in GIST patients refractory to imatinib and in other sarcoma histologies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Metastasis / drug therapy. Salvage Therapy. Sarcoma / drug therapy. Sarcoma / pathology


21. de Bree R, van der Waal I, de Bree E, Leemans CR: Management of adult soft tissue sarcomas of the head and neck. Oral Oncol; 2010 Nov;46(11):786-90
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adult soft tissue sarcomas of the head and neck.
  • Adult soft tissue sarcoma of the head and neck are rare and represent a heterogeneous group of tumours of different histological variants.
  • Malignant fibrous histiocytoma, fibrosarcoma, angiosarcoma and malignant peripheral nerve sheath tumour are the most frequently found sarcoma types in the head and neck.
  • The management of soft tissue sarcomas in the head and neck is primarily surgical.
  • With further insight into the biology of soft tissue sarcoma, modern imaging techniques and new treatment options, we will most certainly be able to improve clinical outcome in patients with soft tissue sarcoma in the upcoming years.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20947413.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


22. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs; 2006 Sep;24(5):435-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
  • BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins.
  • CONCLUSIONS: Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcoma patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Phosphorylcholine / analogs & derivatives. Sarcoma / drug therapy
  • [MeSH-minor] Academies and Institutes. Adult. Aged. Canada. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasms / drug therapy


23. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, Casali PG: Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer; 2006 Jul;42(10):1484-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
  • Trabectedin is a marine-derived cytoxic alkaloid which has shown promising antitumour activity in a variety of human malignancies including sarcoma.
  • Fifty-four patients with advanced sarcoma (age 43 yrs, range 18-70), all pretreated with prior chemotherapy, were enrolled on a named individual basis for treatment with trabectedin.
  • Diagnosis was adult soft tissue sarcoma (STS) in 46 patients, Ewing's family tumour (EFT) in 4, and osteosarcoma (OS) in 4.
  • Among STS patients, 9% had objective responses.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Bone Marrow Diseases / chemically induced. Dioxoles / adverse effects. Drug-Induced Liver Injury. Premedication. Sarcoma / drug therapy. Steroids / therapeutic use. Tetrahydroisoquinolines / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Liver Diseases / prevention & control. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737808.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Steroids; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  •  go-up   go-down


24. Geva R, Jiveliouk I, Inbar M, Meller I, Friedman E, Merimsky O: The co-occurrence of breast cancer and soft tissue sarcoma in a single cohort series. Am J Clin Oncol; 2009 Feb;32(1):34-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The co-occurrence of breast cancer and soft tissue sarcoma in a single cohort series.
  • BACKGROUND: The incidence of breast cancer (BC) and soft tissue sarcoma (STS) in the Israeli general population is 97/10 women and 1.5/10 persons.
  • It is expected that 1.5/10 x 49/10 of the women in the general population will have both BC and STS.
  • METHODS: A retrospective search of 1350 adult STS patient files that were recorded between 1995 and 2005.
  • RESULTS: One hundred thirty-four patients with STS had multiple primary malignancies.
  • BC was observed in 27/64 patients (42%) before/after the STS: BC-first in 19/27, BC-later in 8/27.
  • Of 19 with BC-first the STS was related to radiotherapy in 2, and to lymphedema in 1.
  • Of 8 STS-first, only 1 got chemotherapy before BC.
  • The incidence of BC among all patients with STS-first followed by a second malignancy is 8/58 (14%), or 27/890 (3%) of all women STS-patients in the registry.
  • The incidence of STS among the BC patients was low, and most of our cases were therapy unrelated.
  • Median survival for BC-first was 305 months, versus 213 for STS-first.
  • CONCLUSIONS: BC and STS may naturally occur in the same individual.
  • Practically, BC screening in patients with STS is warranted.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Medullary / pathology. Neoplasms, Second Primary / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194122.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ivanov SM, Tkachev SI, Bokhian BIu, Petrovichev NN, Karapetian RM, Machak GN, Nazarenko AV: [Thermoradiochemotherapy of inoperable soft-tissue sarcoma]. Vopr Onkol; 2005;51(3):350-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thermoradiochemotherapy of inoperable soft-tissue sarcoma].
  • Three groups of patients with inoperable soft-tissue sarcoma received preoperative radiotherapy (57), thermoradiotherapy (102) and thermoradiochemotherapy (16) (n=175).
  • [MeSH-major] Hyperthermia, Induced. Neoadjuvant Therapy / methods. Sarcoma / drug therapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy, Adjuvant / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279101.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


26. Chui CH: Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS). Surg Oncol; 2007 Nov;16(3):187-93
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS).
  • Nonrhabdmyosarcoma soft tissue sarcoma (NRSTS) is a heterogenous group of tumors analyzed as a unique group because of the rarity of each histopathological subtype.
  • Initial information available has been obtained from adult series or pediatric case studies.
  • Identification of sarcoma-specific chromosomal translocations has allowed for more accurate definitive diagnosis.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707639.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 42
  •  go-up   go-down


27. Polsky D, Mastorides S, Kim D, Dudas M, Leon L, Leung D, Woodruff JM, Brennan MF, Osman I, Cordon-Cardo C: Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior. Histol Histopathol; 2006 07;21(7):743-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior.
  • In this study, we examined adult soft tissue sarcomas (ASTS) to determine if alterations of pRB were associated with distinct patterns of pRB expression and clinical outcome.
  • CONCLUSIONS: Inactivation of pRB is common in adult STS, which may be due to either gene loss or post-translational modification, namely hyper-phosphorylation.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Retinoblastoma Protein / metabolism. Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598673.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Retinoblastoma Protein
  •  go-up   go-down


28. Daigeler A, Lehnhardt M, Sebastian A, Belyaev O, Steinstraesser L, Steinau HU, Kuhnen C: Metachronous bilateral soft tissue sarcoma of the extremities. Langenbecks Arch Surg; 2008 Mar;393(2):207-12
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous bilateral soft tissue sarcoma of the extremities.
  • BACKGROUND AND AIMS: Synchronous and heterochronous multiple soft tissue sarcoma of the extremities is very rare.
  • Out of 1,201 of our patients, 4 patients presented with symmetrical bilateral soft tissue sarcoma of the extremities.
  • RESULTS: All tumours were located at the extremities and were diagnosed as leiomyosarcoma in two patients, malignant fibrous histiocytoma and clear cell sarcoma in one patient each.
  • In two patients a second primary sarcoma of the same entity was considered the most likely diagnosis, whereas in one patient a contralateral lymph node metastasis and in one other patient an atypical soft tissue metastasis had to be taken into account.
  • Aside from irradiation effects, exposition to other carcinogenic agents or genetic predisposition, the reasons for the clustering of soft tissue sarcoma in one same patient remain still unclear.
  • CONCLUSION: The interpretation of the bilateral manifestation of soft tissue sarcoma remains open, but predicts an unfavourable outcome.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242894.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Vincenzi B, Frezza AM, Santini D, Tonini G: New therapies in soft tissue sarcoma. Expert Opin Emerg Drugs; 2010 Jun;15(2):237-48
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapies in soft tissue sarcoma.
  • IMPORTANCE OF THE FIELD: Soft tissue sarcomas are rare mesenchymal tumors accounting for < 1% of all adult neoplasia.
  • In the last decade, locally advanced and metastatic soft tissue sarcoma have been managed only through surgery, radiotherapy and standard chemotherapy (mainly based on anthracycline and ifosfamide).
  • Despite the efforts, overall 5-year survival rate in patients with soft tissue sarcomas of all stages remains only 50 - 60%.
  • AREAS COVERED IN THIS REVIEW: In the present article, all the main new molecules under clinical evaluation for the treatment of soft tissue sarcoma are revised by describing the mechanism of action, the biological rationale of their use in sarcoma and by reporting the available data about safety and efficacy, up to 2009.
  • WHAT THE READER WILL GAIN: A brief summary of the standard treatments available at the moment and a complete analysis of the state of art about the development of new target therapies in the management of soft tissue sarcoma.
  • TAKE HOME MESSAGE: The identification of new biological therapies that target soft tissue sarcoma tumorigenesis key points seems to offer a real opportunity of improving the prognosis of this often aggressive disease.
  • In this sense, the best management for soft tissue sarcoma patients is in a clinical trial and participation in clinical trials should be encouraged.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drugs, Investigational / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20465449.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 77
  •  go-up   go-down


30. Talbot SG, Mehrara BJ, Disa JJ, Wong AK, Pusic A, Cordeiro PG, Athanasian EA: Soft-tissue coverage of the hand following sarcoma resection. Plast Reconstr Surg; 2008 Feb;121(2):534-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue coverage of the hand following sarcoma resection.
  • The importance of obtaining widely negative margins has increased the complexity of operations and the importance of soft-tissue and bony reconstruction.
  • The authors review the experience at a single institution of hand reconstruction following sarcoma resection based on prospectively collected data.
  • METHODS: Data were collected for all patients undergoing sarcoma resection by a single surgeon.
  • The most common abnormalities were epithelioid sarcoma (n = 9), soft-tissue malignant fibrous histiocytoma (n = 8), synovial sarcoma (n = 6), and fibrosarcoma (n = 4).
  • CONCLUSIONS: The choice of hand reconstruction method following sarcoma resection depends on a complete knowledge of options, risks, and benefits.
  • Extensive use of a limited number of techniques by the authors' institution appears to contribute to excellent success and complication rates, with safe, reliable, and effective soft-tissue coverage.
  • [MeSH-major] Hand. Reconstructive Surgical Procedures / methods. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / methods. Biopsy. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome. United States / epidemiology


31. Casali PG, Picci P: Adjuvant chemotherapy for soft tissue sarcoma. Curr Opin Oncol; 2005 Jul;17(4):361-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for soft tissue sarcoma.
  • PURPOSE OF REVIEW: To review current state-of-the-art knowledge about adjuvant medical therapy in adult soft tissue sarcomas.
  • SUMMARY: Overall, adjuvant chemotherapy may give some benefit in soft tissue sarcoma.
  • This was mainly shown for extremity soft tissue sarcoma but may also apply to other primary sites.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933469.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 20
  •  go-up   go-down


32. Thomas DM, O'Sullivan B, Gronchi A: Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Rev Anticancer Ther; 2009 Aug;9(8):1145-57
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.
  • Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care.
  • The most common adult subtypes are liposarcomas and leiomyosarcomas, followed by pleomorphic sarcoma/malignant fibros histiocytoma (an entity not always easily distinguishable from dedifferentiated liposarcoma).
  • Pediatric subtypes mainly comprise extraskeletal Ewing sarcoma/pPNET and alveolar rhabdomyosarcoma.
  • Chemotherapy has a limited role in the adjuvant setting for most forms of retroperitoneal sarcoma (excluding pediatric subtypes), but has an increasing role in advanced disease.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Animals. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Child. Combined Modality Therapy. Drug Delivery Systems. Humans. Palliative Care / methods. Radiotherapy, Adjuvant / methods

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671034.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


33. Hartmann JT: Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs; 2007 Mar;18(3):245-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
  • Small round cell sarcoma, such as Ewing/PNET, desmoplastic small round cell sarcoma and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensitive and neoadjuvant protocols regardless of size or overt metastatic disease.
  • A limited number of effective agents available for the treatment of patients with metastatic adult soft-tissue sarcoma exists, which have failed anthracyline and ifosfamide-based chemotherapy.
  • Most other high-grade (grading >I) so-called adult-type soft-tissue sarcomas such as fibro, lipo, pleomorphic and synovial sarcoma are treated with a anthracycline-based regimen with or without ifosfamide as front-line therapy.
  • In this review, the therapeutic activities of drugs currently available as second-line treatment in patients with metastatic soft tissue sarcoma are summarized, providing an overview of contentious or emerging treatment issues.
  • In relapsed 'adult-type' soft-tissue sarcomas trofosfamide, gemcitabine and ecteinascidin (ET-743) appear to be drugs associated with moderate activity and an acceptable toxicity profile.
  • An interesting finding to be noted is that the different drugs have particular effects in distinct subtypes of soft-tissue sarcoma; however, it has to be taken into account that the number of patients included in those phase II trials are limited.
  • The so-called selective therapy targeting vascular endothelial growth factor (receptor), epidermal growth factor receptor, c-kit, Raf kinase or platelet-derived growth factor receptor and bcl-2 antisensing, proteasome, protein kinase C/B, and mammalian target of rabamycin inhibition will continue to be tested in gastrointestinal stromal tumors patients refractory to imatinib mesylate as well as in selected sarcoma subtypes.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264755.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anthracyclines; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Taxoids; 0 / Topoisomerase I Inhibitors; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 91
  •  go-up   go-down


34. Gronchi A, Olmi P, Casali PG: Combined modalities approach for localized adult extremity soft-tissue sarcoma. Expert Rev Anticancer Ther; 2007 Aug;7(8):1135-44
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modalities approach for localized adult extremity soft-tissue sarcoma.
  • Extremity soft-tissue sarcomas are a heterogeneous group of rare neoplasms, characterized by a broad spectrum of biological aggressiveness and a uniform tendency for local failure if not adequately treated.
  • Nevertheless, soft-tissue sarcomas are no longer considered a unique disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Limb Salvage. Sarcoma

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028022.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 90
  •  go-up   go-down


35. Lin PP, Pino ED, Normand AN, Deavers MT, Cannon CP, Ballo MT, Pisters PW, Pollock RE, Lewis VO, Zagars GK, Yasko AW: Periosteal margin in soft-tissue sarcoma. Cancer; 2007 Feb 1;109(3):598-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periosteal margin in soft-tissue sarcoma.
  • BACKGROUND: Soft-tissue sarcomas frequently rest in contact with bone.
  • METHODS: Fifty patients with soft-tissue sarcomas abutting bone were treated at a single institution between 1990 and 2004.
  • In 11 cases a composite resection of bone and soft tissue was performed.
  • In 39 cases the excision involved only soft tissue.
  • Local recurrence in the soft tissues developed in 8 of 50 (16%) patients.
  • There was no statistically significant difference in local recurrence between patients who had composite bone resection and patients who had soft-tissue resection only (P = .87).
  • Composite bone and soft-tissue resections are indicated primarily for frank bone invasion.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Periosteum / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate


36. Albores-Zúñiga O, Padilla-Rosciano AE, Martínez-Said H, Cuéllar-Hubbe M, Ramírez-Bollas J: [Clear cell sarcoma and sentinel lymph node biopsy. Case report and literature review]. Cir Cir; 2006 Mar-Apr;74(2):121-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell sarcoma and sentinel lymph node biopsy. Case report and literature review].
  • [Transliterated title] Sarcoma de células claras y ganglio centinela. Reporte de un caso y revisión de la literatura.
  • The procedure of sentinel node biopsy has been used previously in clear cell sarcoma.
  • The biopsy reported clear cell sarcoma.
  • [MeSH-major] Sarcoma, Clear Cell / pathology. Sentinel Lymph Node Biopsy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Coloring Agents. Humans. Lymph Node Excision / methods. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiography. Male. Neoplasm Staging / methods. Radiography, Thoracic. Staining and Labeling / methods. Technetium Compounds. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887085.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Technetium Compounds
  •  go-up   go-down


37. Farshadpour F, Schaapveld M, Suurmeijer AJ, Wymenga AN, Otter R, Hoekstra HJ: Soft tissue sarcoma: why not treated? Crit Rev Oncol Hematol; 2005 Apr;54(1):77-83
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma: why not treated?
  • BACKGROUND: Soft tissue sarcomas (STS) are uncommon malignancies and elderly STS patients have been reported to receive less definitive treatment compared to young STS patients.
  • METHODS: Patients with primary STS, registered by the Comprehensive Cancer Center North-Netherlands (CCCN) from 1989 to 1999, were analyzed retrospectively with regard to the inclusion-criteria: no primary anti-tumor treatment.
  • RESULTS: From 1989 to 1999, 620 patients (including 56 Kaposi sarcoma) were registered with primary STS.
  • The reasons for no treatment were irresectability of the sarcoma (65%), metastatic disease (11%), comorbidity (4%), poor general health (5%), death prior to therapy (7%) and refusal of therapy (3%) (motivation not documented in 5%).
  • CONCLUSIONS: Thirteen percent of all STS patients within the CCCN region were not treated, 70% of these patients were elderly.
  • Withholding treatment was mostly disease-related (76%), e.g. irresectable retroperitoneal STS or metastatic disease; for 19% of the patients, it was related to their poor general health.
  • The decision to refrain from cancer treatment was justifiable in all these STS patients.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Health Status. Humans. Male. Middle Aged. Motivation. Neoplasm Staging. Netherlands. Prognosis. Retrospective Studies. Withholding Treatment

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780909.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


38. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, Cance WG: Retroperitoneal soft tissue sarcoma. Cancer; 2005 Aug 15;104(4):669-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal soft tissue sarcoma.
  • The objective of the current study was to define the optimal treatment for patients with retroperitoneal soft tissue sarcomas (RPS).
  • [MeSH-major] Digestive System Surgical Procedures. Retroperitoneal Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16003776.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


39. Kakuta Y, Kobayashi Y, Katoh T, Saitoh J, Yazawa K, Hosomi M, Itoh K: [Three cases of retroperitoneal soft tissue sarcoma]. Hinyokika Kiyo; 2006 Apr;52(4):271-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of retroperitoneal soft tissue sarcoma].
  • Soft tissue sarcomas (STS) are rare tumors that comprise only 1% of all malignancies.
  • The retroperitoneum is an uncommon site of origin for them, accounting for about 10% of all STS.
  • It was undifferentiated sarcoma 2,000 g in weight.
  • [MeSH-major] Retroperitoneal Neoplasms / radiography. Sarcoma / radiography. Soft Tissue Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Female. Fibrosarcoma / radiography. Fibrosarcoma / surgery. Humans. Liposarcoma / radiography. Liposarcoma / surgery. Male. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686354.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, Hamada K, Ueda T, Naka N, Kudawara I, Aozasa K: Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res; 2006 May 15;12(10):3070-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of activated AKT expression in soft-tissue sarcoma.
  • PATIENTS AND METHODS: Ninety-three patients (53 males and 40 females), ages ranging from 19 to 77 years (median, 57 years), with localized soft-tissue sarcomas arising in the trunk and extremities, were analyzed.
  • CONCLUSION: p-AKT expression level is a significant prognosticator in soft-tissue sarcoma.
  • [MeSH-major] Proto-Oncogene Proteins c-akt / biosynthesis. Sarcoma / genetics. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Forkhead Transcription Factors / metabolism. Gene Expression Profiling. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Mitogen-Activated Protein Kinase 1 / biosynthesis. Mitogen-Activated Protein Kinase 3 / biosynthesis. Multivariate Analysis. Phosphorylation. Prognosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707604.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Ki-67 Antigen; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


41. Canter RJ, Qin LX, Ferrone CR, Maki RG, Singer S, Brennan MF: Why do patients with low-grade soft tissue sarcoma die? Ann Surg Oncol; 2008 Dec;15(12):3550-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Why do patients with low-grade soft tissue sarcoma die?
  • INTRODUCTION: The patterns of failure and mechanisms of sarcoma-specific death are poorly characterized among the minority of patients with low-grade soft tissue sarcoma (STS) who succumb to disease.
  • METHODS: Between 1982 and 2006, 2,041 patients aged >or=16 years with low-grade STS of all sites were treated with curative intent and prospectively followed at a single institution.
  • In 17 patients (9%), the mechanism of sarcoma-related death could not be verified.
  • CONCLUSION: Among patients with low-grade STS, DOD occurs in approximately 9% of patients.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Jul 1;62(1):184-93 [3383114.001]
  • [Cites] Biometrics. 1978 Dec;34(4):541-54 [373811.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] World J Surg. 1988 Jun;12(3):326-31 [3400243.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1317-29 [1634922.001]
  • [Cites] Arch Surg. 1993 Dec;128(12):1336-43 [8250705.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):165-73 [8129487.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] Cancer. 1996 May 1;77(9):1823-30 [8646680.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):77-82 [10518103.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):402-8 [15578681.001]
  • [Cites] Immunol Res. 2005;32(1-3):231-45 [16106075.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Histopathology. 2006 Jan;48(1):42-50 [16359536.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):791-6 [11821462.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Cancer. 2003 May 15;97(10):2530-43 [12733153.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):432-40 [12734093.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):78-84 [14699038.001]
  • [Cites] Biometrics. 1979 Mar;35(1):25-39 [497336.001]
  • (PMID = 18830667.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA047179-09; United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / P01 CA 047179; United States / NCI NIH HHS / CA / P01 CA047179-09
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS75337; NLM/ PMC2605207
  •  go-up   go-down


42. Mulder RL, Paulides M, Langer T, Kremer LC, van Dalen EC: Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. Cochrane Database Syst Rev; 2010;(2):CD006300
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
  • BACKGROUND: Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma.
  • OBJECTIVES: To compare the possible effectiveness of cyclophosphamide with that of ifosfamide for paediatric and young adult patients with sarcoma.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing cyclophosphamide and ifosfamide for the treatment of different types of sarcoma in paediatric and young adult patients (aged less than 30 years at diagnosis).
  • AUTHORS' CONCLUSIONS: No RCTs or CCTs comparing the effectiveness of cyclophosphamide and ifosfamide in the treatment of bone and soft tissue sarcoma in children and young adults were identified.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Bone Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Ifosfamide / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Child. Humans. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2012;12:CD006300 [23235629.001]
  • (PMID = 20166081.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 35
  •  go-up   go-down


43. Ardeleanu C, Comănescu M, Comănescu V, Andrei F: Uncommon pattern in soft tissues epithelioid sarcoma. Rom J Morphol Embryol; 2005;46(3):229-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon pattern in soft tissues epithelioid sarcoma.
  • Epithelioid sarcoma (ES) is a rare tumor, but extremely versatile, simulating easily both clinically and morphologically multiple benign lesions as granulomas and malignant tumors as achromic melanomas or carcinomas.
  • AIM: To report some peculiar histological and immunophenotypic aspects in soft parts epithelioid sarcoma.
  • MATERIALS AND METHODS: We analyzed retrospectively three cases of epithelioid sarcomas with unusual clinico-morphological (large dimensions), histopathological (absence of necrosis) and immunohistochemical (IHC) patterns selected from 200 consecutive soft parts malignant tumors of "Victor Babeş" National Institute Bucharest files.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD34 / analysis. Child. Humans. Immunohistochemistry. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444310.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34
  •  go-up   go-down


44. Kopp HG, Patel S, Brücher B, Hartmann JT: Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am J Clin Dermatol; 2008;9(4):207-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
  • Soft-tissue sarcomas (STS) include a spectrum of histologically and clinically different tumors.
  • We summarize current treatment options for metastatic STS, including established first-line chemotherapy approaches, mainly with anthracyclines and/or ifosfamide and second-line treatment choices beyond anthracyclines.
  • Until only a few years ago, treatment choices for metastatic STS were easy to review because of the very limited number of active compounds available.
  • However, with the advent of novel therapeutic strategies such as the anti-angiogenic approach and a multitude of novel compounds available both outside and within clinical studies, it has potentially become more difficult to keep track of currently available treatment options for STS and their clinical safety and efficacy.
  • In this practice-oriented article, we therefore review treatment goals in advanced STS and provide an overview of compounds with proven activity in this setting.
  • Anthracyclines with or without ifosfamide are still considered standard of care for most STS subtypes, especially for high-grade tumors.
  • Recently, trabectedin, a DNA minor groove binder initially isolated from a sea sponge, has proven effective and received European approval for use in treatment-refractory STS.
  • In order to be successful, it may be necessary to combine not only different compounds but also different targets beyond the proliferation machinery of sarcoma cells such as tumor angiogenesis, the tumor stromal compartment, or tumor cell oncogene products.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / administration & dosage. Anthracyclines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Humans. Neoplasm Staging. Protein Kinase Inhibitors / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18572972.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 108
  •  go-up   go-down


45. Russo A, Zaottini A: [Diagnosis of synovial sarcoma of the knee accidentally revealed by trauma. Role of ultrasound. Differential diagnosis by scar-hematoma]. Ann Ital Chir; 2009 Mar-Apr;80(2):151-7
MedlinePlus Health Information. consumer health - Knee Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of synovial sarcoma of the knee accidentally revealed by trauma. Role of ultrasound. Differential diagnosis by scar-hematoma].
  • [Transliterated title] Diagnosi di sarcoma sinoviale del ginocchio fortuitamente favorita da evento traumatico. Il contributo dell'ecografia in urgenza al sospetto clinico e la diagnosi differenziale con l'ematoma in fase di cicatrizzazione.
  • Synovial sarcoma accounts for 8-10% of all of the soft tissue sarcomas; it's characterized by high risk of local relapse, even after surgical complete excision, deceiving onset ed slowly growth.
  • Generally arising in the contest of joint or from immediately surrounding anatomical sites, first of all affecting inferior limbs (2/3), a sarcoma of the knee, elective anatomical site, is described, accidentally diagnosed after traumatic event.
  • Exhibiting a very poor 5 year survey, (55%), related to dimension, distal or proximal arising, necrosis rate and grading, it's the most fequently soft tissue malignancy misdiagnosed with benign neoplasms, such as Baker cyst or villonodular pigmented synovitis, considering its deceiving macroscopic and chronological features; the differential diagnosis seems to be very hard, relying on histhological biopsy.
  • [MeSH-major] Cicatrix, Hypertrophic / ultrasonography. Hematoma / ultrasonography. Knee Injuries / ultrasonography. Knee Joint / ultrasonography. Sarcoma, Synovial / ultrasonography. Soft Tissue Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Incidental Findings. Male. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681299.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Armah HB, Parwani AV: Epithelioid sarcoma. Arch Pathol Lab Med; 2009 May;133(5):814-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid sarcoma.
  • They have no normal cellular counterpart and differ from both synovial sarcoma and carcinoma.
  • They account for less than 1% of all soft tissue sarcomas and are usually slow growing, with peak incidence in young adult men and occur predominantly in extremities.
  • [MeSH-major] Sarcoma / secondary. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415960.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


47. Liu QY, Li HG, Chen JY, Liang BL: [Correlation of MRI features to histopathologic grade of soft tissue sarcoma]. Ai Zheng; 2008 Aug;27(8):856-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of MRI features to histopathologic grade of soft tissue sarcoma].
  • BACKGROUND & OBJECTIVE: Peripheral tumor growth pattern plays an important role in the local recurrence and metastases of soft tissue sarcoma.
  • This study was to determine the peripheral growth pattern of soft tissue sarcoma by magnetic resonance imaging (MRI), explore its correlation to histological grade, and assess biological features of soft tissue sarcoma before operation.
  • METHODS: MRI was performed in 59 patients with soft tissue sarcoma.
  • RESULTS: The histological grade of soft tissue sarcoma was closely related to the margin appearance (P<0.05): the margin was well defined in 60.0% grade I tumors, and poorly defined in 60.0% grade III tumors.
  • CONCLUSION: The peripheral tumor growth pattern is related with histological grade, and may reflect the biological behaviors of soft tissue sarcoma.
  • [MeSH-major] Magnetic Resonance Imaging. Sarcoma / diagnosis. Sarcoma / pathology. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Extremities. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / pathology. Histiocytoma, Malignant Fibrous / diagnosis. Histiocytoma, Malignant Fibrous / pathology. Humans. Infant. Liposarcoma / diagnosis. Liposarcoma / pathology. Male. Middle Aged. Neoplasm Staging. Young Adult


48. Kiatisevi P, Asavamongkolkul A, Phimolsarnti R, Waikakul S, Benjarassamerote S: The outcomes and prognostic factors of patients with soft-tissue sarcoma. J Med Assoc Thai; 2006 Mar;89(3):334-42
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcomes and prognostic factors of patients with soft-tissue sarcoma.
  • The present study evaluates the outcomes and prognostic factors in patients with soft-tissue sarcomas of the extremities, trunk, head and neck region.
  • [MeSH-major] Extremities. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Sarcoma / mortality. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Thailand / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16696417.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


49. Seaward JR, Wilson PA, Stone CA: Computer-aided surgical planning in the treatment of soft-tissue sarcoma. Ann R Coll Surg Engl; 2010 Nov;92(8):639-42
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided surgical planning in the treatment of soft-tissue sarcoma.
  • INTRODUCTION: Soft-tissue sarcoma resections are often highly complex procedures that demand meticulous pre-operative planning in order to maximise the potential for complete excision with clear margins, while preserving vital neurovascular structures and muscle groups.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Surgery, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Humans. Magnetic Resonance Imaging. Male. Preoperative Care / methods. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20659359.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3229368
  •  go-up   go-down


50. Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, Hamada K, Ueda T, Naka N, Kudawara I, Aozasa K: Reassessment of the 1993 Osaka grading system for localized soft tissue sarcoma in Japan. Anticancer Res; 2006 Nov-Dec;26(6C):4665-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reassessment of the 1993 Osaka grading system for localized soft tissue sarcoma in Japan.
  • BACKGROUND: The Osaka system for soft-tissue sarcoma grading was proposed through an analysis of soft-tissue sarcoma (STS), treated from 1964 to 1989.
  • CONCLUSION: Osaka grading is a useful system for the decision-making of therapeutic modalities for STS.
  • [MeSH-major] Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Japan. Male. Middle Aged. Multivariate Analysis. Prognosis. Severity of Illness Index

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214324.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


51. Xin FY, Rana N, Ming Z, Lang YB: Alveolar soft part sarcoma of the retro peritoneum. J Cancer Res Ther; 2010 Jan-Mar;6(1):117-9
Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar soft part sarcoma of the retro peritoneum.
  • Alveolar Soft Part Sarcoma (ASPS), also called Alveolar Soft-Tissue Sarcoma, is a rare type of soft-tissue neoplasm with a poor long term prognosis.
  • [MeSH-major] Retroperitoneal Neoplasms / pathology. Sarcoma, Alveolar Soft Part / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479565.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


52. Svarvar C, Böhling T, Berlin O, Gustafson P, Follerås G, Bjerkehagen B, Domanski HA, Sundby Hall K, Tukiainen E, Blomqvist C, Scandinavian Sarcoma Group Leiomyosarcoma Working Group: Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer; 2007 Jan 15;109(2):282-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group.
  • BACKGROUND: Leiomyosarcoma of nonvisceral soft tissues is an uncommon malignant tumor; thus, only small numbers of cases have been reported.
  • This study was based on a large series of patients from the Scandinavian Sarcoma Group Register acquired during a 15-year period (from 1986 to 2001).
  • Only patients who received their treatment at a specialist sarcoma center were included.
  • CONCLUSIONS: The long-term prognosis for patients with subcutaneous and deep-seated soft tissue leiomyosarcoma remains poor despite the ability to achieve adequate local control through nonmutilating surgery with or without radiotherapy.
  • [MeSH-major] Leiomyosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Registries / statistics & numerical data. Scandinavian and Nordic Countries. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17154171.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Kasper B, Gil T, Awada A: Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol; 2007 Jul;19(4):336-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?
  • PURPOSE OF REVIEW: We give an overview on the emerging compounds for patients with soft tissue sarcoma.
  • RECENT FINDINGS: Soft tissue sarcomas are a heterogeneous group of tumours that arise predominantly from the embryonic mesoderm.
  • They account for fewer than 1% of all adult malignancies.
  • The prognosis of patients with advanced metastatic soft tissue sarcoma remains poor, with disease-free survival at 5 years below 10%.
  • SUMMARY: Understanding of the molecular biology and pathogenesis of soft tissue sarcomas has been enhanced, and in the near future this should translate into molecular tumour characterization and development of new therapeutic strategies.
  • [MeSH-major] Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545796.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Receptors, Growth Factor; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 32
  •  go-up   go-down


54. Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, Yamashita T, Chuman H, Beppu Y, Tani Y, Hasegawa T: Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer; 2005 May 1;103(9):1881-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
  • BACKGROUND: Little is known about the expression of receptor tyrosine kinases in adult soft tissue sarcomas (STS).
  • In the current study, the authors analyzed the expression of epidermal growth factor receptor (EGFR), ERBB2, and KIT in 281 patients with STS who were treated in a single institution.
  • METHODS: The current study included 281 adult patients with STS of the extremity and trunk who were diagnosed and treated in the National Cancer Center, Tokyo.
  • Expression was assessed using immunohistochemical stains for EGFR, ERBB2, and KIT on formalin-fixed, paraffin-embedded tissue sections by standard avidin-biotin peroxidase complex technique and EGFR detection system.
  • CONCLUSIONS: EGFR overexpression was found to be a negative prognostic factor of adult STS, which is strongly associated with histologic grade.
  • STS patients with EGFR overexpression may benefit from treatment with currently available biospecific inhibitors for EGFR.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Sarcoma / metabolism
  • [MeSH-minor] Adult. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Paraffin Embedding. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15772959.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


55. Rimner A, Brennan MF, Zhang Z, Singer S, Alektiar KM: Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh. Cancer; 2009 Jan 1;115(1):149-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh.
  • METHODS: A total of 255 patients with primary soft tissue sarcoma (STS) of the thigh were identified in our sarcoma database (1982-2002).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Edema / complications. Female. Fractures, Bone / complications. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Reoperation. Sarcoma / drug therapy. Sarcoma / radiotherapy. Sarcoma / surgery. Surgical Procedures, Operative / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 19090010.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Barner-Rasmussen I, Popov P, Böhling T, Tarkkanen M, Sampo M, Tukiainen E: Microvascular reconstruction after resection of soft tissue sarcoma of the leg. Br J Surg; 2009 May;96(5):482-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvascular reconstruction after resection of soft tissue sarcoma of the leg.
  • BACKGROUND: Limb-sparing surgery and satisfactory functional outcome is the goal of extremity soft tissue sarcoma (STS) surgery.
  • Tissue defects after tumour excision are often extensive, and microvascular reconstruction is frequently required.
  • METHODS: Seventy-three patients with STS of the leg requiring microvascular reconstruction were treated between 1985 and 2006.
  • Microvascular reconstruction is safe and reliable in lower extremity STS reconstruction.
  • [MeSH-major] Postoperative Complications / etiology. Sarcoma / surgery. Skin Neoplasms / surgery. Surgical Flaps / blood supply. Vascular Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / mortality. Amputation / statistics & numerical data. Disease-Free Survival. Female. Humans. Leg. Length of Stay. Male. Microcirculation. Middle Aged. Neoplasm Metastasis. Risk Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19358178.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


57. Nelson AA, Frassica FJ, Gordon TA, Deune EG: Cost analysis of functional restoration surgery for extremity soft-tissue sarcoma. Plast Reconstr Surg; 2006 Jan;117(1):277-83
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost analysis of functional restoration surgery for extremity soft-tissue sarcoma.
  • METHODS: Patients receiving either functional restoration surgery or soft-tissue-only reconstruction following extremity soft-tissue sarcoma excision were identified.
  • Fifteen of these procedures (eight upper extremity, seven lower extremity) required functional restoration surgery; 54 of these procedures (13 upper extremity, 41 lower extremity) required only soft-tissue coverage.
  • CONCLUSION: Although functional restoration surgery is more costly than soft-tissue reconstruction alone, the authors believe that the associated better functional outcome justifies its performance.
  • [MeSH-major] Extremities. Reconstructive Surgical Procedures / economics. Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps / economics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Costs and Cost Analysis. Female. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / surgery. Length of Stay. Liposarcoma / surgery. Male. Middle Aged. Recovery of Function. United States

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404280.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Hui AC, Ngan SY, Wong K, Powell G, Choong PF: Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience. Eur J Surg Oncol; 2006 Dec;32(10):1159-64
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience.
  • AIM: Radiotherapy has been shown to improve local control in combination with limb-sparing or conservative surgery in the management of localised soft tissue sarcoma.
  • METHODS: Consecutive patients with localised extremity or truncal soft tissue sarcoma who presented between January 1996 and December 2000 and treated with preoperative radiotherapy followed by limb-sparing surgery were reviewed.
  • CONCLUSION: Preoperative radiotherapy followed by surgery provides effective local control in the management of soft tissue sarcoma.
  • [MeSH-major] Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Radiation Injuries. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765559.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Indelicato DJ, Meadows K, Gibbs CP Jr, Morris CG, Scarborough MT, Zlotecki RA: Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):267-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma.
  • PURPOSE: The management of isolated local recurrence of soft-tissue sarcoma is therapeutically complex, and functional conservative management is preferable to radical or amputative salvage surgery.
  • This study reviews the University of Florida experience using conservative resection and reirradiation to manage isolated local recurrences of soft-tissue sarcoma.
  • CONCLUSIONS: Salvage therapy for management of locally recurrent soft-tissue sarcoma is challenging, and the effects of reoperation and reirradiation can be severe.
  • [MeSH-major] Sarcoma / radiotherapy. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707824.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Müller M, Bickert B, Germann G, Sauerbier M: [Soft-tissue sarcoma of the forearm and hand. Plastic surgical management]. Chirurg; 2008 Jul;79(7):682-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft-tissue sarcoma of the forearm and hand. Plastic surgical management].
  • Twenty patients with soft-tissue sarcomas of the hand and forearm were treated in our department between January 1995 and January 2005.
  • The most common tumor was myxoid fibrous histiocytoma, followed by synovial cell sarcoma.
  • These results show the necessity of plastic surgical reconstruction of the forearm and hand as an integral component of modern sarcoma therapy.
  • [MeSH-major] Forearm / surgery. Hand / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Limb Salvage. Male. Microsurgery. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Surgical Flaps

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437325.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Segal NH, Blachere NE, Guevara-Patiño JA, Gallardo HF, Shiu HY, Viale A, Antonescu CR, Wolchok JD, Houghton AN: Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun; 2005 Feb 1;5:2
Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics.
  • Cancer-testis or germ cell antigens (GCAs) are a category of tumor antigens expressed by male germ cells and by cancers of diverse histological origin, but not usually by normal adult somatic tissue.
  • In this study, we exploit oligonucleotide technology to identify genes in melanoma and soft tissue sarcoma (STS) that display a cancer-testis/GCA expression profile.
  • Among our findings are the expression of PRAME in monophasic synovial sarcoma, PRAME and NY-ESO-1 in myxoid/round cell liposarcoma, and SSX2 and members of the GAGE family in malignant fibrous histiocytoma.
  • Furthermore, the proto-oncogene DBL/MCF2 was identified as encoding a novel candidate GCA expressed by clear cell sarcoma/melanoma of soft parts (MSP).
  • [MeSH-major] Antigens, Neoplasm / genetics. Gene Expression Profiling. Melanoma / immunology. Sarcoma / immunology. Skin Neoplasms / immunology. Testis / metabolism
  • [MeSH-minor] Adult. CD8-Positive T-Lymphocytes / immunology. Computational Biology. Gene Expression. Humans. Infant. Male. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15683221.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33049; United States / NCI NIH HHS / CA / CA47179
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


62. Ishikawa M, Ishizuka O, Nakayama T, Kobayashi S, Igawa Y, Nishizawa O, Sugimoto K, Yamashita T, Matsushita T: Alveolar soft-part sarcoma of the retroperitoneum. Int J Urol; 2006 Oct;13(10):1355-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar soft-part sarcoma of the retroperitoneum.
  • The pathological diagnosis was alveolar soft-part sarcoma (ASPS).
  • Alveolar soft-part sarcoma is a rare soft-tissue tumor that accounts for approximately 0.5-1% of soft-tissue sarcomas.
  • [MeSH-major] Retroperitoneal Neoplasms / diagnosis. Sarcoma, Alveolar Soft Part / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17010020.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


63. Sleijfer S, Seynaeve C, Verweij J: Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist; 2005 Nov-Dec;10(10):833-41
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.
  • The group of soft tissue sarcomas in adult patients is a heterogeneous group with more than 40 different subtypes.
  • While local treatment remains the mainstay for localized disease, systemic chemotherapy can importantly contribute in the treatment of advanced soft tissue sarcoma.
  • This review addresses the current available data on chemotherapy for adult patients with soft tissue sarcoma, excluding gastrointestinal stromal tumor, the Ewing-like sarcomas, and other small blue round cell tumors.
  • In addition, it is increasingly recognized that future research in soft tissue sarcoma should focus on the identification of tumor factors that can serve as targets for treatment and that the diverse tumor subtypes should be analyzed separately for their sensitivity to systemic treatment.
  • [MeSH-major] Sarcoma / drug therapy
  • [MeSH-minor] Adult. Anthracyclines / administration & dosage. Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314294.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  • [Number-of-references] 50
  •  go-up   go-down


64. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, Duggal A, Steadman P: Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg; 2006 Mar;76(3):104-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical margin and its influence on survival in soft tissue sarcoma.
  • BACKGROUND: The goal of surgeons treating soft tissue sarcoma is to gain local control, to avoid risk of local recurrence and to avoid compromise of the patient's potential survival.
  • METHODS: Two hundred and seventy-nine patients who presented with soft tissue sarcoma without metastatic disease were analysed.
  • [MeSH-major] Sarcoma / mortality. Sarcoma / surgery. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2006 Mar;76(3):97 [16626338.001]
  • (PMID = 16626341.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


65. Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza S, Wassermann B, Picci P, Perris R: NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res; 2009 Jan;27(1):135-40
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients.
  • Enhanced expression levels of NG2 proteoglycan in presurgical original lesions of soft-tissue sarcoma (STS) patients defines with 55% probability the immediate (i.e., within 12 months postsurgery) risk in these individuals to develop postsurgical secondary lesions, independently of any other clinical trait.
  • In our cohort of high-grade STS cases, transcription of NG2 also showed a 81-fold amplification in metastatic lesions, when compared to primitive ones, and this gene overexpression was accompanied by an abundant but nonuniform in situ expression of its product.
  • Therefore, minimally invasive assessment of the transcription levels of the NG2 gene represents a parameter capable of predicting the arising of metastatic disease within a definite postsurgery time interval, and affords in adjunct in the definition of life expectance in STS patients.
  • [MeSH-major] Antigens / biosynthesis. Gene Expression Regulation, Neoplastic. Proteoglycans / biosynthesis. Sarcoma / metabolism. Sarcoma / pathology. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Prognosis. Transcription, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634019.001).
  • [ISSN] 1554-527X
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  •  go-up   go-down


66. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF: Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol; 2008 Oct;15(10):2749-56
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb infusion for advanced soft tissue sarcoma of the extremity.
  • We report our experience with ILI for the treatment of soft tissue sarcoma (STS).
  • METHODS: From our prospective database, 21 patients with STS of the limb treated with ILI between 1994 and 2007 were identified.
  • ILI is a minimally invasive alternative to isolated limb perfusion for patients with advanced STS of the extremity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / pathology. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Dactinomycin / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648882.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; Q41OR9510P / Melphalan
  •  go-up   go-down


67. Teixeira LE, Araújo ID, de Andrade MA, Gomes RA, Salles PG, Ghedini DF: [Local recurrence in soft tissue sarcoma: prognostic factors]. Rev Col Bras Cir; 2009 Oct;36(5):377-81
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrence in soft tissue sarcoma: prognostic factors].
  • OBJECTIVE: To determinate the prognostic factors associated with the local relapse in patients treated for soft tissue sarcoma in extremities.
  • METHODS: Retrospectively, 30 patients were evaluated after being treated with surgical resection of soft tissue sarcoma located in extremities, with a outcome of 36,5 +/- 12,2 months.
  • [MeSH-major] Leg. Neoplasm Recurrence, Local / epidemiology. Sarcoma / epidemiology. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20069148.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


68. Tateishi U, Hasegawa T, Yamamoto S, Yamaguchi U, Yokoyama R, Kawamoto H, Satake M, Arai Y: Incidence of multiple primary malignancies in a cohort of adult patients with soft tissue sarcoma. Jpn J Clin Oncol; 2005 Aug;35(8):444-52
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of multiple primary malignancies in a cohort of adult patients with soft tissue sarcoma.
  • OBJECTIVE: Some studies to date have suggested the development of multiple primary malignancies in patients with soft tissue sarcoma.
  • The current study was performed to quantify the risk of development of multiple primary malignancies in adult patients with soft tissue sarcoma.
  • METHODS: A total of 406 consecutive patients who were diagnosed with soft tissue sarcoma were identified in the study analysis.
  • RESULTS: A total of 35 patients with soft tissue sarcoma (9%), having preceding (n = 15) and subsequent (n = 20) malignancies other than soft tissue sarcoma were documented.
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / epidemiology. Breast Neoplasms / epidemiology. Cohort Studies. Confounding Factors (Epidemiology). Female. Fibrosarcoma / therapy. Humans. Incidence. Lung Neoplasms / epidemiology. Male. Middle Aged. Multivariate Analysis. Osteosarcoma / epidemiology. Prognosis. Proportional Hazards Models. Prostatic Neoplasms / epidemiology. ROC Curve. Risk

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024533.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Mendenhall WM, Indelicato DJ, Scarborough MT, Zlotecki RA, Gibbs CP, Mendenhall NP, Mendenhall CM, Enneking WF: The management of adult soft tissue sarcomas. Am J Clin Oncol; 2009 Aug;32(4):436-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of adult soft tissue sarcomas.
  • Soft tissue sarcomas are a relatively rare, heterogeneous group of tumors arising from mesenchymal tissues and occurring almost anywhere in the body.
  • Often, these procedures cannot be achieved either because of the location and extent of the sarcoma or anticipated functional deficit.
  • [MeSH-major] Neoplasm Invasiveness / pathology. Sarcoma / mortality. Sarcoma / therapy. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Care / methods. Preoperative Care / methods. Radiation Injuries / prevention & control. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Surgical Procedures, Operative / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19657238.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


70. Zhang B, Tomita Y, Ch'ng E, Qiu Y, He J, Jin YF, Tomoeda M, Hamada K, Ueda T, Aozasa K: Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. Ann Surg Oncol; 2009 Jul;16(7):1925-37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma.
  • Expression of FOXO1 in soft tissue sarcoma (STS) and its correlation with clinicopathological factors and prognostic significance were evaluated.
  • METHODS: Expression of phosphorylated FOXO1 (p-FOXO1) in localized STS from 84 adult patients, 50 male and 34 female, aged 15-89 (median 54) years, was evaluated by immunohistochemistry.
  • CONCLUSIONS: The prognostic significance of p-FOXO1 expression level in STS was demonstrated.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Forkhead Transcription Factors / biosynthesis. Sarcoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Phosphorylation. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408047.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


71. Stoeckle E, Gardet H, Coindre JM, Kantor G, Bonichon F, Milbéo Y, Thomas L, Avril A, Bui BN: Prospective evaluation of quality of surgery in soft tissue sarcoma. Eur J Surg Oncol; 2006 Dec;32(10):1242-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of quality of surgery in soft tissue sarcoma.
  • BACKGROUND: Prospective application of the French Sarcoma Group (FSG) method of surgery reporting in soft tissue sarcoma (STS) in a single centre.
  • METHODS: Patients with primary STS of the extremities or trunk wall consecutively operated at the same institution from January 1996 to December 2002 were evaluated for local recurrence (LR).
  • CONCLUSION: This first prospective evaluation of surgery reporting in STS evidences a fourfold, highly discriminating difference in LR between resections R0 and R1.
  • [MeSH-major] Extremities. Neoplasm Recurrence, Local. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793237.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Sampath S, Hitchcock YJ, Shrieve DC, Randall RL, Schultheiss TE, Wong JY: Radiotherapy and extent of surgical resection in retroperitoneal soft-tissue sarcoma: multi-institutional analysis of 261 patients. J Surg Oncol; 2010 Apr 1;101(5):345-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and extent of surgical resection in retroperitoneal soft-tissue sarcoma: multi-institutional analysis of 261 patients.
  • BACKGROUND AND OBJECTIVE: To examine the impact of adjuvant radiotherapy (RT) and surgical technique on survival in retroperitoneal soft-tissue sarcoma.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Retrospective Studies. Treatment Failure

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20119974.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


73. Moore LF, Kransdorf MJ, Buskirk SJ, O'Connor MI, Menke DM: Radiation-induced pseudotumor following therapy for soft tissue sarcoma. Skeletal Radiol; 2009 Jun;38(6):579-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced pseudotumor following therapy for soft tissue sarcoma.
  • PURPOSE: The purpose of this study was to describe the prevalence and imaging appearance of radiation induced pseudotumors in patients following radiation therapy for extremity soft tissue sarcomas.
  • MATERIALS AND METHODS: We retrospectively reviewed the serial magnetic resonance (MR) images of 24 patients following radiation therapy for extremity soft tissue sarcomas.
  • Primary tumors were malignant fibrous histiocytoma (n = 13), leiomyosarcoma (n = 6), liposarcoma (n = 3), synovial sarcoma (n = 1), and extraskeletal chondrosarcoma (n = 1).
  • [MeSH-major] Neoplasms, Radiation-Induced / epidemiology. Radiotherapy, Conformal / statistics & numerical data. Sarcoma / epidemiology. Sarcoma / radiotherapy. Soft Tissue Neoplasms / epidemiology. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Comorbidity. Female. Florida / epidemiology. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Risk Assessment / methods. Risk Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221738.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. van Dalen T, Plooij JM, van Coevorden F, van Geel AN, Hoekstra HJ, Albus-Lutter Ch, Slootweg PJ, Hennipman A, Dutch Soft Tissue Sarcoma Group: Long-term prognosis of primary retroperitoneal soft tissue sarcoma. Eur J Surg Oncol; 2007 Mar;33(2):234-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term prognosis of primary retroperitoneal soft tissue sarcoma.
  • AIMS: To evaluate the result of treatment and long-term outcome of a population-based cohort of patients with retroperitoneal soft tissue sarcoma (RSTS).
  • [MeSH-major] Retroperitoneal Neoplasms / epidemiology. Sarcoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Netherlands / epidemiology. Population Surveillance. Prognosis. Retrospective Studies. Risk Factors. Survival Rate / trends. Time Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081725.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. D'Annibale M, Cosimelli M, Covello R, Stasi E: Liposarcoma of the colon presenting as an endoluminal mass. World J Surg Oncol; 2009;7:78
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Liposarcoma is one of the most common soft tissue sarcoma of adult life, usually occurring in the retroperitoneum and the extremities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Apr;36(4):378-80 [10841651.001]
  • [Cites] Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):1016-8 [19272723.001]
  • [Cites] Acta Oncol. 2003;42(5-6):516-31 [14596510.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):281-5 [15306943.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1257-67 [15371941.001]
  • [Cites] Am Surg. 2004 Sep;70(9):775-8 [15481292.001]
  • [Cites] Am J Gastroenterol. 1972 Aug;58(2):172-6 [5056514.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Dis Colon Rectum. 1984 Jul;27(7):485-8 [6745024.001]
  • [Cites] Cancer. 1985 May 15;55(10):2482-90 [3986744.001]
  • [Cites] Acta Chir Scand. 1986 May;152:389-91 [3739551.001]
  • [Cites] Mt Sinai J Med. 1989 Jan;56(1):62-4 [2784186.001]
  • [Cites] Am J Surg Pathol. 1992 Nov;16(11):1051-8 [1471725.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • [Cites] Ulster Med J. 1994 Apr;63(1):111-3 [8658985.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):398-407 [9164509.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2853-60 [16289617.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):652-6 [16773759.001]
  • [Cites] Dig Dis Sci. 2007 Dec;52(12):3377-80 [17393311.001]
  • [Cites] Surg Clin North Am. 2008 Jun;88(3):483-520, v-vi [18514695.001]
  • [Cites] Surg Today. 2008;38(12):1129-32 [19039641.001]
  • [Cites] J Gastrointest Cancer. 2007;38(2-4):160-3 [18972225.001]
  • [Cites] Am J Clin Oncol. 2009 Aug;32(4):353-5 [19363435.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):179-84 [11266523.001]
  • (PMID = 19852822.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2771004
  •  go-up   go-down


76. Ferguson PC, Griffin AM, O'Sullivan B, Catton CN, Davis AM, Murji A, Bell RS, Wunder JS: Bone invasion in extremity soft-tissue sarcoma: impact on disease outcomes. Cancer; 2006 Jun 15;106(12):2692-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone invasion in extremity soft-tissue sarcoma: impact on disease outcomes.
  • BACKGROUND: The purpose of the current study was to evaluate histologic bone invasion as a predictor of oncologic outcome in extremity soft-tissue sarcoma (STS) patients presenting to a specialty sarcoma center between 1986 and 2001.
  • METHODS: All patients who underwent surgery for extremity STS were identified from the prospective database at the study institution.
  • RESULTS: In a review of 874 patients with STS of the extremity, 48 patients (5.5%) had evidence of bone invasion.
  • CONCLUSIONS: In a small percentage of patients with STS, bone resection may be required to obtain an adequate surgical margin, thereby limiting the risk of local tumor recurrence.
  • [MeSH-major] Bone Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Bone and Bones / pathology. Bone and Bones / surgery. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Prognosis. Proportional Hazards Models. Prospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700041.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG, Gronchi A: Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. Cancer; 2010 May 15;116(10):2429-36
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma.
  • BACKGROUND: This study was conducted to develop a histology-specific nomogram to predict postoperative overall survival (OS) at 5 and 10 years in primary retroperitoneal soft tissue sarcoma (STS).
  • METHODS: Data registered at a single institution (National Cancer Institute, Milan, Italy) prospective sarcoma database were used.
  • In the present analysis, patients with primary localized retroperitoneal STS resected with curative intent between 1985 and 2007 were included.
  • Known prognostic variables, such as age, tumor burden, histologic variant (as reviewed by a sarcoma pathologist), grade, and surgical margins were considered as putative predictors.
  • CONCLUSIONS: A histology-specific nomogram for retroperitoneal STS is now available.
  • [MeSH-major] Nomograms. Retroperitoneal Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Models, Statistical. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Cancer 2010. (c) 2010 American Cancer Society.
  • (PMID = 20209615.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


78. Lucas DR, Kshirsagar MP, Biermann JS, Hamre MR, Thomas DG, Schuetze SM, Baker LH: Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation. Oncologist; 2008 Apr;13(4):451-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.
  • Histologic response to chemotherapy is generally regarded as an independent prognostic variable in bone sarcomas, both osteosarcoma and Ewing's sarcoma.
  • In soft tissue sarcomas, however, descriptions of histologic alterations from chemotherapy and correlative outcome studies are much more limited.
  • Herein we report clinicopathological findings from a homogeneously treated group of 31 patients with tumor stage T2 grade 3 extremity soft tissue sarcomas treated with the same neoadjuvant chemotherapy followed by surgical excision, treated by the same medical oncologist and orthopedic surgeon.
  • Chemotherapy induces profound tissue alterations in soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Prognosis. Prospective Studies. Treatment Outcome


79. Latt LD, Turcotte RE, Isler MH, Wong C: Case series. Soft-tissue sarcoma of the foot. Can J Surg; 2010 Dec;53(6):424-31
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case series. Soft-tissue sarcoma of the foot.
  • BACKGROUND: We reviewed cases of soft-tissue sarcoma of the foot to gain insight into the presentation, treatments and outcomes for this rare disease and to determine whether limb-salvage surgery yields reasonable functional and oncological outcomes.
  • METHODS: We reviewed the cases of 16 patients treated by 2 of us (R.T. and M.I.) for soft-tissue sarcoma of the foot over a 15-year period.
  • Histological diagnosis was synovial sarcoma for 7 of 16 patients.The tumours were evenly distributed among the hindfoot, midfoot and forefoot.
  • Free tissue transfer (n = 9) and radiation therapy (n = 12) were used in most cases.
  • Second, limb salvage was usually possible, but it required accepting marginal resections, relying on free tissue transfer to obtain coverage and using radiation therapy to obtain local control.
  • [MeSH-major] Foot / surgery. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation / statistics & numerical data. Female. Follow-Up Studies. Free Tissue Flaps / statistics & numerical data. Humans. Limb Salvage / statistics & numerical data. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant / statistics & numerical data

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):710-6 [10762742.001]
  • [Cites] Foot Ankle Int. 2008 Jul;29(7):690-8 [18785419.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):679-85 [11078615.001]
  • [Cites] Acta Orthop Scand. 2000 Oct;71(5):488-95 [11186407.001]
  • [Cites] J Bone Joint Surg Br. 2001 Nov;83(8):1149-55 [11764430.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Orthop Surg (Hong Kong). 2002 Dec;10(2):173-8 [12493931.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):485-92 [12518373.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):476-82 [15078635.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1344-8 [4045526.001]
  • [Cites] Semin Oncol. 1989 Aug;16(4):289-96 [2667143.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jul;75(4):658-60 [8331127.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] Acta Orthop Scand Suppl. 1994 Jun;259:1-31 [8042499.001]
  • [Cites] Acta Orthop Scand. 1994 Oct;65(5):553-8 [7801762.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Qual Life Res. 1996 Oct;5(5):508-16 [8973131.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] J Pediatr Surg. 1997 Aug;32(8):1181-4 [9269966.001]
  • [Cites] J Surg Oncol. 1997 Oct;66(2):81-7 [9354161.001]
  • [Cites] Arch Phys Med Rehabil. 1999 Jun;80(6):615-8 [10378484.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):10-7 [15827772.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):62-5 [16462505.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):206-11 [10797333.001]
  • (PMID = 21092437.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2993038
  •  go-up   go-down


80. Smith R, Pak Y, Kraybill W, Kane JM 3rd: Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. Eur J Surg Oncol; 2009 Apr;35(4):356-61
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy.
  • AIMS: To identify clinicopathologic and treatment variables associated with long-term overall survival (OS) in soft tissue sarcoma (STS) patients with lung metastases undergoing pulmonary metastasectomy (PM).
  • METHODS: Retrospective review of 94 STS PM patients with an actual follow-up > or = 5 years.
  • CONCLUSIONS: Less than 20% of STS PM patients will survive 5 years.
  • [MeSH-major] Lung Neoplasms / secondary. Retroperitoneal Neoplasms / mortality. Sarcoma / mortality. Sarcoma / secondary. Uterine Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Extremities / surgery. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294807.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Ch'ng E, Tomita Y, Zhang B, He J, Hoshida Y, Qiu Y, Morii E, Nakamichi I, Hamada K, Ueda T, Aozasa K: Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer; 2007 Jul 1;110(1):164-72
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CD100 expression in soft tissue sarcoma.
  • The expression of CD100 in soft tissue sarcoma (STS) and its correlation with clinicopathologic factors and prognostic significance were evaluated.
  • METHODS: Expression levels of CD100 in patients with localized STS were evaluated immunohistochemically on paraffin-embedded sections from 81 patients, including 47 men and 34 women with a median age of 54 years.
  • CONCLUSIONS: The results from this study indicated the demonstrated prognostic significance of CD100 expression in STS.
  • [MeSH-major] Antigens, CD / biosynthesis. Sarcoma / pathology. Semaphorins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Analysis. Tumor Burden

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17520683.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD100 antigen; 0 / Ki-67 Antigen; 0 / Semaphorins
  •  go-up   go-down


82. Krempien R, Roeder F, Oertel S, Weitz J, Hensley FW, Timke C, Funk A, Lindel K, Harms W, Buchler MW, Debus J, Treiber M: Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):773-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma.
  • PURPOSE: This study assesses the long-term outcome of patients with retroperitoneal soft-tissue sarcomas treated by maximal resection in combination with intraoperative electron-beam therapy (IOERT) and postoperative external-beam radiotherapy.
  • METHODS AND MATERIALS: From 1991 to 2004, 67 patients were treated with curative intent for primary (n = 26) or recurrent (n = 41) retroperitoneal soft-tissue sarcoma.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Intraoperative Period. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682152.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Lehnert T, Cardona S, Hinz U, Willeke F, Mechtersheimer G, Treiber M, Herfarth C, Buechler MW, Schwarzbach MH: Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol; 2009 Sep;35(9):986-93
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival.
  • AIM: To evaluate local control for long-term prognosis in retroperitoneal soft-tissue sarcoma (primary tumors (PT) and local recurrence (LR)).
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Retroperitoneal Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138832.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


84. Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miyagi T, Maeda Y, Kitagawa Y, Kadono Y, Konaka H, Namiki M: Role of surgical resection in adult urological soft tissue sarcoma: 25-year experience. Urol Int; 2010;84(3):309-14
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of surgical resection in adult urological soft tissue sarcoma: 25-year experience.
  • INTRODUCTION: As adult urological soft tissue sarcomas (STS) are rare, there have been few recent large-scale studies of these tumors.
  • This report describes a single institutional experience of adult urological STS over 25 years.
  • PATIENTS AND METHODS: The study population consisted of 25 adult patients with histologically diagnosed STS arising in the urinary tract, male genital system, or retroperitoneum between January 1983 and July 2008.
  • CONCLUSIONS: Surgical resection, regardless of status of surgical resection margin, contributed to a favorable prognosis in adult patients with locally advanced or metastatic urological STS.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Urologic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20389161.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


85. Fisher C: Epithelioid sarcoma of Enzinger. Adv Anat Pathol; 2006 May;13(3):114-21
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid sarcoma of Enzinger.
  • Epithelioid sarcoma was named in 1970 in a classic paper by Enzinger, who expanded the observations in a larger series in 1985.
  • He defined a sarcoma with a peak incidence in young adult males and a predilection for extremities, involving subcutis or deeper tissue and extending along tendon sheaths or aponeuroses.
  • The tumor has no normal cellular counterpart and differs from both synovial sarcoma and carcinoma.
  • Epithelioid sarcoma has a high recurrence rate, which can be reduced by adequate surgery, and up to 40% metastasize, to regional lymph nodes, to lung, and other locations including scalp.
  • Thirty-six years after Enzinger's original account, epithelioid sarcoma remains a clinically and pathologically distinct, indolent but aggressive sarcoma of indeterminate lineage.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778474.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


86. Prantl L, Roll C, Feser D, Schreml S, Nerlich M, Mayr E, Füchtmeier B: [Reduction of the amputation rate in bone and soft tissue sarcoma by interdisciplinary cooperation]. Handchir Mikrochir Plast Chir; 2006 Jun;38(3):178-84
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reduction of the amputation rate in bone and soft tissue sarcoma by interdisciplinary cooperation].
  • On the basis of three patients with bone and soft tissue sarcoma,we would like to illustrate the necessity of a well working inter-disciplinary cooperation of radiologists, internal oncologists, radiation therapists, orthopaedic surgeons and plastic surgeons.
  • Functional extremity preservation in sarcoma patients can be achieved by a good interdisciplinary management without im-pairing the total prognosis of the patients.
  • Patients with sarcoma should be treated in centres in which all specialised divisions are experienced and well trained in the treatment of tumour patients.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. Leg / surgery. Limb Salvage. Osteosarcoma / surgery. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Amputation. Follow-Up Studies. Humans. Male. Middle Aged. Patient Care Team. Prognosis. Surgical Flaps. Time Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883503.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Davidge K, Bell R, Ferguson P, Turcotte R, Wunder J, Davis AM: Patient expectations for surgical outcome in extremity soft tissue sarcoma. J Surg Oncol; 2009 Oct 1;100(5):375-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient expectations for surgical outcome in extremity soft tissue sarcoma.
  • This study examines the relationship between pre-treatment outcome expectations and post-operative function and health-related quality of life (HRQoL) in patients with extremity soft tissue sarcoma (ESTS).
  • [MeSH-major] Attitude to Health. Limb Salvage. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Educational Status. Extremities / surgery. Female. Humans. Male. Middle Aged. Multivariate Analysis. Quality of Life. Recovery of Function. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19444815.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Li EX, Zhang YT, Shang JT, Xu Z, Geng Y, Li SM, Shi F, Wu YY: [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma]. Ai Zheng; 2006 Aug;25(8):1048-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
  • BACKGROUND & OBJECTIVES: Clinical study suggests that 72-hour continuous infusion (CIV) of MAID regimen is more effective and achieves longer time of no progression than ADR-based two-drug regimen in advanced soft tissue sarcoma (ASTS) treatment, but has no improvement on the long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma, Synovial / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Neutropenia / chemically induced. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965692.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


89. Lahat G, Tuvin D, Wei C, Anaya DA, Bekele BN, Lazar AJ, Pisters PW, Lev D, Pollock RE: New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol; 2008 Oct;15(10):2739-48
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New perspectives for staging and prognosis in soft tissue sarcoma.
  • BACKGROUND: Data suggest that the current American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging criteria merit further evaluation.
  • We sought to identify and validate factors as enhanced descriptors of STS clinical behavior.
  • METHODS: Prospectively accrued data were analyzed for 1,091 AJCC stage I to III primary STS patients who had complete macroscopic resection at our institution from 1996 to 2007.
  • RESULTS: In contrast to the current AJCC STS staging system, which stratifies size into T1 (</=5 cm) and T2 (>5 cm) groups, we demonstrated three distinct cohorts (P < 0.0001): T1 (</=5 cm; 5-year OS 85%), T2 (5 to 15 cm; OS 68%), and T3 (>15 cm; OS 52%).
  • Recurrence during follow-up was the most significant risk factor for STS-specific mortality (P < 0.0001).
  • CONCLUSION: Tumor size and grade in the AJCC STS staging system need revision; moreover, primary site, histologic subtype, margin status, and recurrence offer additional relevant prognostic insight.
  • Incorporation of these factors may enhance the AJCC staging system, thereby further facilitating individualized therapeutic strategies for STS patients.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Oct;15(10):2643 [18685895.001]
  • (PMID = 18521685.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Morii T, Mochizuki K, Takushima A, Okazaki M, Satomi K: Soft tissue reconstruction using vascularized tissue transplantation following resection of musculoskeletal sarcoma: evaluation of oncologic and functional outcomes in 55 cases. Ann Plast Surg; 2009 Mar;62(3):252-7
MedlinePlus Health Information. consumer health - Wounds and Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue reconstruction using vascularized tissue transplantation following resection of musculoskeletal sarcoma: evaluation of oncologic and functional outcomes in 55 cases.
  • Oncologic resection of musculoskeletal sarcoma sometimes requires reconstruction with vascularized soft tissue transplantation.
  • [MeSH-major] Bone Neoplasms / surgery. Reconstructive Surgical Procedures. Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps / blood supply. Wounds and Injuries / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Recovery of Function. Treatment Outcome. Young Adult


91. Sampo M, Tarkkanen M, Huuhtanen R, Tukiainen E, Böhling T, Blomqvist C: Impact of the smallest surgical margin on local control in soft tissue sarcoma. Br J Surg; 2008 Feb;95(2):237-43
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of the smallest surgical margin on local control in soft tissue sarcoma.
  • BACKGROUND: The aim was to review a single-institution experience of a prospective treatment protocol for soft tissue sarcoma of the extremity and trunk wall, with particular focus on the smallest surgical margin leading to local control.
  • METHODS: The study included 270 patients who had surgery for soft tissue sarcoma at Helsinki University Central Hospital between 1987 and 1997.
  • On multivariable analysis, the smallest surgical margin around the sarcoma (after radiotherapy) was prognostic for local control.
  • A surgical margin of 2-3 cm provided reasonable local control of soft tissue sarcoma, even without radiotherapy.
  • [MeSH-major] Neoplasms, Connective Tissue / surgery. Sarcoma / surgery
  • [MeSH-minor] Abdominal Wall. Adult. Aged. Amputation / statistics & numerical data. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Protocols. Extremities. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Prospective Studies. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 17703500.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


92. Chandrasekar CR, Wafa H, Grimer RJ, Carter SR, Tillman RM, Abudu A: The effect of an unplanned excision of a soft-tissue sarcoma on prognosis. J Bone Joint Surg Br; 2008 Feb;90(2):203-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of an unplanned excision of a soft-tissue sarcoma on prognosis.
  • We investigated whether our policy of routine re-excision of the tumour bed after an unplanned excision of a soft-tissue sarcoma was justified.
  • Between April 1982 and December 2005, 2201 patients were referred to our hospital with the diagnosis of soft-tissue sarcoma, of whom 402 (18%) had undergone an unplanned excision elsewhere.
  • We concluded that our policy of routine re-excision after unplanned excision of soft-tissue sarcoma was justified in view of the high risk of finding residual tumour.
  • [MeSH-major] Guideline Adherence / standards. Neoplasm Recurrence, Local / surgery. Referral and Consultation / standards. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Practice Guidelines as Topic. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18256089.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Kasper B: Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. Rev Recent Clin Trials; 2007 Sep;2(3):206-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma.
  • Soft tissue sarcomas are a heterogeneous group of tumours arising predominantly from the embryonic mesoderm.
  • They account for less than 1% of all adult malignancies.
  • The prognosis of patients with advanced metastatic soft tissue sarcoma remains poor with a disease-free survival at 5 years less than 10%.
  • Moreover, we give an overview on the emerging compounds for patients with soft tissue sarcoma including recent developments of targeted therapy focusing on antiangiogenic and immunomodulatory drugs, Bcl-2 antisense therapy, raf kinase and mTOR inhibition, minor groove binders, and other agents being developed.
  • [MeSH-major] Sarcoma / therapy


94. Jakob J, Wenz F, Dinter DJ, Ströbel P, Hohenberger P: Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2009 Nov 1;75(3):810-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
  • PURPOSE: To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS).
  • PATIENTS AND METHODS: A cohort of 15 consecutive patients with nonmetastasized, primary high-grade or locally recurrent Stage III (n = 14) or IIb (n = 1) STS not amenable to surgical resection without significant organ or extremity function loss was prospectively investigated.
  • CONCLUSIONS: Preoperative chemoradiation with temozolomide and IMRT can be administered safely and with promising efficacy in patients with locally advanced STS.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Radiotherapy, Intensity-Modulated. Sarcoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Nausea / etiology. Postoperative Complications. Prospective Studies. Radiation Injuries / etiology. Radiotherapy Dosage. Remission Induction. Tumor Burden. Vomiting / etiology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307066.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


95. Al-Refaie WB, Habermann EB, Dudeja V, Vickers SM, Tuttle TM, Jensen EH, Virnig BA: Extremity soft tissue sarcoma care in the elderly: insights into the generalizability of NCI Cancer Trials. Ann Surg Oncol; 2010 Jul;17(7):1732-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremity soft tissue sarcoma care in the elderly: insights into the generalizability of NCI Cancer Trials.
  • BACKGROUND: The projected increase in older persons in the United States, their underrepresentation in clinical trials, and the rarity of extremity soft tissue sarcomas (ESTS) limit our understanding of ESTS care in the elderly.
  • RESULTS: More than 30% of adult ESTS were diagnosed in patients older than 65 years.
  • A significant trend was observed between increasing age and decreased use of sarcoma-directed surgery and delivery of radiotherapy after limb-sparing surgery for high-grade or T2 tumors.
  • Although our multivariable analyses showed that decreased use of sarcoma-directed surgery was only limited to age 85 + years, it also showed that older age predicted poorer cancer-specific mortality following sarcoma-directed surgery (P < .0001).
  • CONCLUSIONS: In this US population-based study, the decreased use of sarcoma-directed surgery in the elderly was only limited to those older than 85 years.
  • [MeSH-major] Extremities / surgery. Sarcoma / surgery

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Jul;17(7):1725-6 [20390459.001]
  • (PMID = 20354801.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / RC2 MD004797
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. McKenzie G, Raby N, Ritchie D: Pictorial review: Non-neoplastic soft-tissue masses. Br J Radiol; 2009 Aug;82(981):775-85
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pictorial review: Non-neoplastic soft-tissue masses.
  • As a tertiary centre for soft-tissue sarcomas, numerous non-neoplastic masses are referred to our institution.
  • The purpose of this article is to review the imaging characteristics of these non-neoplastic lesions and highlight the features that help differentiate these lesions from a soft-tissue sarcoma.
  • [MeSH-major] Sarcoma / diagnosis. Soft Tissue Injuries / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Amyloidosis / diagnosis. Aneurysm / diagnosis. Calcinosis / diagnosis. Child. Cysts / diagnosis. Diagnosis, Differential. Female. Fibroma / diagnosis. Hematoma / diagnosis. Hernia / diagnosis. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Muscles / injuries. Myositis Ossificans / diagnosis. Soft Tissue Infections / diagnosis. Tomography, X-Ray Computed / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064599.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


97. Canter RJ, Martinez SR, Tamurian RM, Wilton M, Li CS, Ryu J, Mak W, Monsky WL, Borys D: Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol; 2010 Oct;17(10):2578-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma.
  • BACKGROUND: Limited data exist regarding the radiographic and histologic response of soft tissue sarcoma (STS) to neoadjuvant radiotherapy (RT).
  • METHODS: Between February 2000 and January 2009, a total of 25 patients aged >16 years with intermediate- or high-grade primary STS of all sites were treated with neoadjuvant RT followed by definitive resection.
  • CONCLUSIONS: Radiologic and near-complete pathologic responses are rare events after preoperative RT for STS.
  • Knowledge of these historical response rates is important for the evaluation of novel neoadjuvant therapies for patients with STS.
  • [MeSH-major] Neoadjuvant Therapy. Sarcoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radiotherapy. Prospective Studies. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / radiography. Retroperitoneal Neoplasms / radiotherapy. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3203-9 [11432887.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1147-53 [19577863.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):522-6 [15380587.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1500-4 [3040219.001]
  • [Cites] J Surg Oncol. 1994 Oct;57(2):111-4 [7934061.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):508-17 [16491338.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):371-9 [16752414.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Aug;6(8):1251-60 [16925491.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):715-20 [18245531.001]
  • [Cites] Oncologist. 2008;13 Suppl 2:1-3 [18434630.001]
  • [Cites] Oncologist. 2008;13 Suppl 2:32-40 [18434637.001]
  • [Cites] J Orthop Sci. 2008 Jul;13(4):304-12 [18696187.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1480-7 [18448271.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3550-60 [18830667.001]
  • [Cites] Radiology. 2009 May;251(2):447-56 [19261927.001]
  • [Cites] Cancer. 2009 Jul 15;115(14):3254-61 [19472403.001]
  • [Cites] Int J Hyperthermia. 2009 Jun;25(4):289-98 [19670096.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):346-54 [11986186.001]
  • (PMID = 20556523.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024146
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2941714
  •  go-up   go-down


98. Bokhian BIu, Karapetian RM, Ivanov SM, Mekhtieva NI: [Results of repeat large-scale dissection of soft-tissue sarcoma following non-radical removal]. Vopr Onkol; 2005;51(3):372-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of repeat large-scale dissection of soft-tissue sarcoma following non-radical removal].
  • The reports deals with the data on repeat large-scale dissection of soft-tissue sarcoma following non-radical removal in 23 patients (13 males and 10 females , aged 14-75; mean age 42+/-30.2 yrs).
  • [MeSH-major] Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Dissection. Female. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279106.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


99. Miki Y, Ngan S, Clark JC, Akiyama T, Choong PF: The significance of size change of soft tissue sarcoma during preoperative radiotherapy. Eur J Surg Oncol; 2010 Jul;36(7):678-83
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of size change of soft tissue sarcoma during preoperative radiotherapy.
  • AIM: To assess the significance of change in tumour size during preoperative radiotherapy in patients with soft tissue sarcoma (STS).
  • METHODS: A retrospective review of 91 cases with STS was performed.
  • Inclusion criteria were localised extremity and truncal STS with measurable disease, older than 18 years, treated with preoperative radiotherapy and wide local excision, in the period between January 1966 and December 2005.
  • Patients with head and neck STS, or who received neoadjuvant chemotherapy were excluded.
  • CONCLUSION: Increase in tumour size during preoperative radiotherapy for soft tissue sarcoma does not seem to associate with inferior local tumour control or compromise survival.
  • [MeSH-major] Neoadjuvant Therapy / methods. Sarcoma / pathology. Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Dose Fractionation. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Radiotherapy, Adjuvant. Survival Analysis. Thallium Radioisotopes. Treatment Outcome. Victoria

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20547446.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


100. Clark MA, Thomas JM: Delay in referral to a specialist soft-tissue sarcoma unit. Eur J Surg Oncol; 2005 May;31(4):443-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delay in referral to a specialist soft-tissue sarcoma unit.
  • BACKGROUND: Soft-tissue sarcoma is a rare neoplasm which can occur almost anywhere in the body.
  • METHODS: A prospective audit was undertaken in 216 patients referred to a specialist unit with suspected or proven soft-tissue sarcoma over a 12 month period.
  • RESULTS: There were 159 patients with previously untreated soft-tissue sarcomas.
  • CONCLUSIONS: A fifth of patients with soft-tissue sarcoma encountered important delays in referral to this specialist unit.
  • [MeSH-major] Referral and Consultation / statistics & numerical data. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Medical Audit. Middle Aged. Prospective Studies. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837054.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement